Back to search
FDAFDA · Food and drugs·Recall number D-1059-2020

Theophylline (Anhydrous) Extended-Release Tablets, 400 mg, 100-count bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC 29033-001-01.

Published April 1, 2020 · Recall initiated: March 6, 2020

Summary

FDA records drug Class II recall D-1059-2020, published April 1, 2020 and initiated March 6, 2020. Recalling firm: Nostrum Laboratories Inc; Status: Terminated; Reported quantity: 4722 bottles; Lot: Lot: THE190501, Exp 11/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: poor manufacturing practices resulted in Labeling: Incorrect or Missing Lot and/or Exp Date, product incorrectly labeled with incorrect lot and expiration date.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nostrum Laboratories Inc
Distributor
TN, MO
Lot
Lot: THE190501, Exp 11/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Theophylline (Anhydrous) Extended-Release Tablets, 400 mg, 100-count bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC 29033-001-01. recalled?

Yes. FDA published recall D-1059-2020 on April 1, 2020. Reported hazard: CGMP Deviations: poor manufacturing practices resulted in Labeling: Incorrect or Missing Lot and/or Exp Date, product incorrectly labeled with incorrect lot and expiration date.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail